These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 30836009)

  • 1. Nonsense-mediated RNA Decay Pathway Inhibition Restores Expression and Function of W1282X CFTR.
    Keenan MM; Huang L; Jordan NJ; Wong E; Cheng Y; Valley HC; Mahiou J; Liang F; Bihler H; Mense M; Guo S; Monia BP
    Am J Respir Cell Mol Biol; 2019 Sep; 61(3):290-300. PubMed ID: 30836009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene-specific nonsense-mediated mRNA decay targeting for cystic fibrosis therapy.
    Kim YJ; Nomakuchi T; Papaleonidopoulou F; Yang L; Zhang Q; Krainer AR
    Nat Commun; 2022 May; 13(1):2978. PubMed ID: 35624092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional rescue of c.3846G>A (W1282X) in patient-derived nasal cultures achieved by inhibition of nonsense mediated decay and protein modulators with complementary mechanisms of action.
    Laselva O; Eckford PD; Bartlett C; Ouyang H; Gunawardena TN; Gonska T; Moraes TJ; Bear CE
    J Cyst Fibros; 2020 Sep; 19(5):717-727. PubMed ID: 31831337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exon-skipping antisense oligonucleotides for cystic fibrosis therapy.
    Kim YJ; Sivetz N; Layne J; Voss DM; Yang L; Zhang Q; Krainer AR
    Proc Natl Acad Sci U S A; 2022 Jan; 119(3):. PubMed ID: 35017301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense oligonucleotide splicing modulation as a novel Cystic Fibrosis therapeutic approach for the W1282X nonsense mutation.
    Oren YS; Avizur-Barchad O; Ozeri-Galai E; Elgrabli R; Schirelman MR; Blinder T; Stampfer CD; Ordan M; Laselva O; Cohen-Cymberknoh M; Kerem E; Bear CE; Kerem B
    J Cyst Fibros; 2022 Jul; 21(4):630-636. PubMed ID: 34972649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CFTR mRNAs with nonsense codons are degraded by the SMG6-mediated endonucleolytic decay pathway.
    Sanderlin EJ; Keenan MM; Mense M; Revenko AS; Monia BP; Guo S; Huang L
    Nat Commun; 2022 Apr; 13(1):2344. PubMed ID: 35487895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation.
    Mutyam V; Libby EF; Peng N; Hadjiliadis D; Bonk M; Solomon GM; Rowe SM
    J Cyst Fibros; 2017 Jan; 16(1):24-29. PubMed ID: 27707539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin.
    Linde L; Boelz S; Nissim-Rafinia M; Oren YS; Wilschanski M; Yaacov Y; Virgilis D; Neu-Yilik G; Kulozik AE; Kerem E; Kerem B
    J Clin Invest; 2007 Mar; 117(3):683-92. PubMed ID: 17290305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Analysis of Combinatorial Pharmacological Treatments to Correct Nonsense Mutations in the CFTR Gene.
    Venturini A; Borrelli A; Musante I; Scudieri P; Capurro V; Renda M; Pedemonte N; Galietta LJV
    Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open reading frame correction using splice-switching antisense oligonucleotides for the treatment of cystic fibrosis.
    Michaels WE; Pena-Rasgado C; Kotaria R; Bridges RJ; Hastings ML
    Proc Natl Acad Sci U S A; 2022 Jan; 119(3):. PubMed ID: 35017302
    [No Abstract]   [Full Text] [Related]  

  • 11. Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor.
    Xue X; Mutyam V; Tang L; Biswas S; Du M; Jackson LA; Dai Y; Belakhov V; Shalev M; Chen F; Schacht J; J Bridges R; Baasov T; Hong J; Bedwell DM; Rowe SM
    Am J Respir Cell Mol Biol; 2014 Apr; 50(4):805-16. PubMed ID: 24251786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased mRNA and protein stability of W1282X limits response to modulator therapy.
    Aksit MA; Bowling AD; Evans TA; Joynt AT; Osorio D; Patel S; West N; Merlo C; Sosnay PR; Cutting GR; Sharma N
    J Cyst Fibros; 2019 Sep; 18(5):606-613. PubMed ID: 30803905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correctors and Potentiators Rescue Function of the Truncated W1282X-Cystic Fibrosis Transmembrane Regulator (CFTR) Translation Product.
    Haggie PM; Phuan PW; Tan JA; Xu H; Avramescu RG; Perdomo D; Zlock L; Nielson DW; Finkbeiner WE; Lukacs GL; Verkman AS
    J Biol Chem; 2017 Jan; 292(3):771-785. PubMed ID: 27895116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Correctors and Potentiators Enhance Translational Readthrough in CFTR Nonsense Mutations.
    Mutyam V; Sharma J; Li Y; Peng N; Chen J; Tang LP; Falk Libby E; Singh AK; Conrath K; Rowe SM
    Am J Respir Cell Mol Biol; 2021 May; 64(5):604-616. PubMed ID: 33616476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense oligonucleotide-mediated correction of CFTR splicing improves chloride secretion in cystic fibrosis patient-derived bronchial epithelial cells.
    Michaels WE; Bridges RJ; Hastings ML
    Nucleic Acids Res; 2020 Jul; 48(13):7454-7467. PubMed ID: 32520327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of premature termination codon mutations on CFTR mRNA abundance in human nasal epithelium and intestinal organoids: a basis for read-through therapies in cystic fibrosis.
    Clarke LA; Awatade NT; Felício VM; Silva IA; Calucho M; Pereira L; Azevedo P; Cavaco J; Barreto C; Bertuzzo C; Gartner S; Beekman J; Amaral MD
    Hum Mutat; 2019 Mar; 40(3):326-334. PubMed ID: 30488522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of adenine base editing and homology-independent targeted integration strategies to correct the cystic fibrosis causing variant, W1282X.
    Mention K; Cavusoglu-Doran K; Joynt AT; Santos L; Sanz D; Eastman AC; Merlo C; Langfelder-Schwind E; Scallan MF; Farinha CM; Cutting GR; Sharma N; Harrison PT
    Hum Mol Genet; 2023 Nov; 32(23):3237-3248. PubMed ID: 37649273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergy between Readthrough and Nonsense Mediated Decay Inhibition in a Murine Model of Cystic Fibrosis Nonsense Mutations.
    McHugh DR; Cotton CU; Hodges CA
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Robust Stimulation of W1282X-CFTR Channel Activity by a Combination of Allosteric Modulators.
    Wang W; Hong JS; Rab A; Sorscher EJ; Kirk KL
    PLoS One; 2016; 11(3):e0152232. PubMed ID: 27007499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.